Evidence map›Paper›PMID 39308168›Full record

Trial reportCancer2024

Cardiovascular disease and stroke following cancer and cancer treatment in older adults.

Jaidyn Muhandiramge, John R Zalcberg, Erica T Warner, Galina Polekhina, Peter Gibbs, G J van Londen, Wendy B Bernstein, Finlay Macrae, Andrew Haydon, Jeanne Tie and 9 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jaidyn MuhandiramgeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-6999-802X
John R ZalcbergSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Erica T WarnerClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2671-0313
Galina PolekhinaSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Peter GibbsThe Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
G J van LondenDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Wendy B BernsteinWalter Reed National Military Medical Center, Bethesda, Maryland, USA.
Finlay MacraeDepartment of Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Andrew HaydonDepartment of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.
Jeanne TieThe Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Jeremy L MillarSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Victoria J MarSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Lucy GatelyDepartment of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.
Andrew TonkinSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Leslie FordDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
Asad UmarDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
Andrew T ChanClinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Suzanne G OrchardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-0211-3183

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
Monash UniversityNational Health and Medical Research Council 1127060National Health and Medical Research Council 334047NCI NIH HHS P30 CA047904NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682NIH HHS 3U19 AG062682-02S1NIH HHS P30 CA047904NIH HHS U01 AG029824NIH HHS U19 AG062682Victorian Cancer Agency
6 · The paper itself

Abstract

backgroundCancer survivors can be at risk of cardiovascular disease (CVD) because of either their malignancy or its treatment. Although studies linking cancer and CVD exist, few examine risk in older adults, the impact of cancer treatment, or the effect of aspirin on reducing risk in this cohort.

methodsThe authors conducted a secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial to investigate the impact of cancer and cancer treatment on a composite CVD end point comprising hospitalization for heart failure (HHF), myocardial infarction (MI), and stroke.

resultsOf 15,454 Australian and US ASPREE participants, 1392 had an incident cancer diagnosis. Rates of CVD were greater in the cancer risk-set compared to the cancer-free risk-set (20.8 vs. 10.3 events per 1000 person-years; incidence rate ratio, 2.03; 95% confidence interval, 1.51-2.66), with increased incidence seen across MI, HHF, overall stroke, and ischemic stroke. Increased incidence remained after adjustment for clinically significant risk factors for CVD. Incidence was greatest in metastatic, hematological, and lung cancer. Chemotherapy was associated with increased risk of CVD. Similar rates of CVD were seen across aspirin and placebo groups.

conclusionsIncidence of CVD, including MI, HHF, and ischemic stroke, was increased in older adults with cancer. Aspirin did not impact CVD incidence. Risk may be higher in those with metastatic, hematological, and lung cancer, and following chemotherapy.

Indexed as

AspirinCardiovascular DiseasesNeoplasmsStrokeAgedAged, 80 and overAntineoplastic AgentsAustraliaCancer SurvivorsFemaleHumansIncidenceMaleMyocardial InfarctionRisk FactorsUnited StatesAntineoplastic AgentsAspirincancercardiovascular diseaseelderlystroke

Identifiers

PMID39308168
PMCPMC11560579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.